文献速递甲状腺疾病

2023年Bethesda甲状腺细胞病理学报告系统

The 2023 Bethesda System for Reporting Thyroid Cytopathology.
PubMed 文献 · Thyroid · 2023-07-08

第三版为6个诊断类别统一命名,更新并细化各类别恶性风险(ROM),提供平均ROM及癌症风险预期范围,简化意义不明的异型性亚分类,新增儿童甲状腺疾病讨论及分子检测和临床影像章节。

要点

  • 第三版为6个诊断类别统一命名:无诊断意义、良性、意义不明的异型性、滤泡性肿瘤、可疑恶性、恶性。
  • 各类别均给出平均恶性风险(ROM)及癌症风险预期范围,基于第二版后数据更新细化。
  • 意义不明的异型性简化为2个亚组,依据隐含ROM和分子谱分析。

核心结论

  • 第三版Bethesda系统为甲状腺细针穿刺提供标准化类别报告,更新恶性风险并简化意义不明的异型性亚分类。

研究设计与样本

  • 该文为Bethesda甲状腺细胞病理学报告系统第三版,基于前两版成功经验并纳入第二版后新数据。

主要发现

  • 第三版为6个诊断类别统一命名,并提供每个类别的平均恶性风险及癌症风险预期范围。
  • 意义不明的异型性简化为2个亚组,依据隐含恶性风险和分子谱分析。
  • 新增儿童甲状腺疾病讨论,包括儿童恶性风险和管理算法。
  • 新增两个章节:一个讨论分子和辅助检测在甲状腺细胞病理学中的扩展应用,另一个总结甲状腺疾病的临床视角和影像学发现。

关键数值与推荐

  • 6个诊断类别:无诊断意义、良性、意义不明的异型性、滤泡性肿瘤、可疑恶性、恶性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the publication of the first edition in 2010, The Bethesda System for Reporting Thyroid Cytopathology has allowed cytopathologists to use a standardized, category-based reporting system for thyroid fine needle aspirations. The third edition builds on the success of the 2 earlier editions and offers several key updates. The most important is the assignment of a single name for each of the 6 diagnostic categories: (i) nondiagnostic; (ii) benign; (iii) atypia of undetermined significance; (iv) follicular neoplasm; (v) suspicious for malignancy; and (vi) malignant. Each of the categories has an implied risk of malignancy (ROM), which has been updated and refined based on data reported after the second edition. The third edition offers an average ROM for each category, in addition to the expected range of cancer risk. The atypia of undetermined significance subcategorization is simplified into 2 subgroups based on the implied ROM and molecular profiling. A discussion of pediatric thyroid disease has been added, and pediatric ROMs and management algorithms are discussed in the relevant sections. Nomenclature has been updated to align with the 2022 World Health Organization Classification of Thyroid Neoplasms. Two new chapters have been added: one that addresses the significant and expanded use of molecular and ancillary testing in thyroid cytopathology, and another that summarizes clinical perspectives and imaging findings in thyroid disease.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ali SZ, Baloch ZW, Cochand-Priollet B, et al. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2023. PMID: 37427847. doi:10.1089/thy.2023.0141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。